Insulin glargine LA is under clinical development by Gan & Lee Pharmaceuticals and currently in Pre-Registration for Type 2 Diabetes. According to GlobalData, Pre-Registration drugs for Type 2 Diabetes have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Insulin glargine LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Insulin glargine LA overview
Insulin glargine (Basalin) is a long-acting insulin analog. Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is formulated as solution, injected once-daily through the subcutaneous route. It is indicated for the improvement of glycemic control in adults as well as children with type 1 diabetes mellitus. It is also employed for controlling hyperglycemia in adults with type 2 diabetes mellitus.
Insulin glargine is under development for the treatment of type 1 diabetes and type 2 diabetes. It is administered through subcutaneous route. The drug candidate acts by targeting insulin receptor (IR).
Gan & Lee Pharmaceuticals overview
Gan & Lee Pharmaceuticals (Gan & Lee) is a biopharmaceutical company. It carries out the research and development, production and sales of recombinant insulin analog APIs and injections. The company product portfolio includes long-acting insulin glargine injection, fast-acting insulin lispro injection, insulin aspart injection, lispro mixed injection and premixed protamine human insulin mixed injection. Gan & Lee also offers cover-related medical devices, including reusable insulin injection pens and disposable pen needles. The company utilizes its patented intramolecular chaperone technology for the production of recombinant human insulin and insulin analogs. Gan & Lee is headquartered in Beijing, China.
For a complete picture of Insulin glargine LA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
